Skip to main content
    I

    Ideaya Biosciences Inc (IDYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $30.36
    -1.47 (-4.62%)

    Market Cap: $3.08B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ideaya Biosciences Inc (IDYA) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Ideaya Biosciences (IDYA) trades at 85.5x sales and 2.9x book value. Its P/S of 85.5x is above its 5-year median of 20.9x. Its forward P/E is 4.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E4.7x
    Price to sales85.5x
    Price to book2.9x
    PEGN/A
    FCF yield-11.2%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S85.5x20.9xN/A
    P/B2.9x2.6xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 of the 7 year ends shown that have a P/S, its P/S ranged from 14.0x in 2025 to 320.7x in 2024. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$34.5714.0x3.0x
    2024$25.70320.7x2.1x
    2023$35.5884.7x3.7x
    2022$18.1714.4x2.5x
    2021$23.6429.2x3.0x
    2020$14.0020.6x2.1x
    2019$7.50N/A1.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About IDYA

    What is IDYA's forward P/E ratio?

    Ideaya Biosciences has a forward P/E ratio of 4.7x.

    What is IDYA's price to sales ratio?

    Ideaya Biosciences has a price to sales ratio of 85.5x.